Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
Commentary|Articles|October 6, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
MFN Raises the Stakes for Japan Launch Pricing
Author(s)Na Wei
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Advertisement
Advertisement
Japan launch pricing has become more consequential against the backdrop of the U.S. most-favored-nation (MFN) policy. Japan is included in the reference basket contemplated under several MFN models, meaning a low launch price can affect pricing well beyond the domestic market.
Related to this article
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Advertisement
Advertisement